Cargando...
Suppression of autophagy by BCR/ABL
Imatinib and second generation BCR/ABL tyrosine kinase inhibitors (TKIs) serve now as standard therapies for patients with chronic myelogenous leukemia (CML); however, CML stem cells are intrinsically insensitive to the cell death-inducing effects of TKIs, allowing the persistence of a “reservoir” o...
Gardado en:
| Publicado en: | Leuk Lymphoma |
|---|---|
| Main Authors: | , |
| Formato: | Artigo |
| Idioma: | Inglês |
| Publicado: |
2011
|
| Assuntos: | |
| Acceso en liña: | https://ncbi.nlm.nih.gov/pmc/articles/PMC7416844/ https://ncbi.nlm.nih.gov/pubmed/21250825 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.3109/10428194.2010.546913 |
| Tags: |
Engadir etiqueta
Sen Etiquetas, Sexa o primeiro en etiquetar este rexistro!
|